Beam Therapeutics Valuation
Is BEAM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BEAM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BEAM *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BEAM *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BEAM *?
Other financial metrics that can be useful for relative valuation.
What is BEAM *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$1.70b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | -4.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BEAM *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 12.7x | ||
ARDX Ardelyx | 9x | 32.8% | US$1.4b |
MIRM Mirum Pharmaceuticals | 6.9x | 25.0% | US$1.6b |
688520 Sinocelltech Group | 8.3x | 26.7% | CN¥18.0b |
RYTM Rhythm Pharmaceuticals | 26.4x | 44.7% | US$2.6b |
BEAM * Beam Therapeutics | 4.5x | -30.9% | Mex$1.7b |
Price-To-Sales vs Peers: BEAM * is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (29.3x).
Price to Earnings Ratio vs Industry
How does BEAM *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: BEAM * is good value based on its Price-To-Sales Ratio (4.5x) compared to the Global Biotechs industry average (10.8x).
Price to Sales Ratio vs Fair Ratio
What is BEAM *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BEAM *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.